Record Information
Version1.0
Creation Date2016-05-25 18:39:42 UTC
Update Date2016-11-09 01:17:32 UTC
Accession NumberCHEM022565
Identification
Common NameDoxorubicinol
ClassSmall Molecule
DescriptionA member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties.
Contaminant Sources
  • HMDB Contaminants - Urine
Contaminant TypeNot Available
Chemical Structure
Thumb
Synonyms
ValueSource
13-DihydrodoxorubicinChEBI
AdriamycinolChEBI
Antibiotic 27706RpChEBI
DOXOLChEBI
Adriamycinol hydrochlorideHMDB
Adriamycinol, 8S-(8alpha,8R*,10alpha)-isomerHMDB
Chemical FormulaC27H31NO11
Average Molecular Mass545.535 g/mol
Monoisotopic Mass545.190 g/mol
CAS Registry Number54193-28-1
IUPAC Name(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-8-[(1S)-1,2-dihydroxyethyl]-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
Traditional Name(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-8-[(1S)-1,2-dihydroxyethyl]-6,8,11-trihydroxy-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
SMILESCOC1=CC=CC2=C1C(=O)C1=C(C(O)=C3C[C@](O)(C[C@H](O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C3=C1O)[C@@H](O)CO)C2=O
InChI IdentifierInChI=1S/C27H31NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15-17,22,29-31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,16-,17-,22+,27-/m0/s1
InChI KeyNKZRZOVSJNSBFR-FEMMEMONSA-N
Chemical Taxonomy
Description belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassAnthracyclines
Sub ClassNot Available
Direct ParentAnthracyclines
Alternative Parents
Substituents
  • Anthracycline
  • Anthracyclinone-skeleton
  • Aminoglycoside core
  • Tetracenequinone
  • 9,10-anthraquinone
  • 1,4-anthraquinone
  • Anthracene
  • Hexose monosaccharide
  • Glycosyl compound
  • O-glycosyl compound
  • Tetralin
  • Anisole
  • Aryl ketone
  • Alkyl aryl ether
  • Amino saccharide
  • Oxane
  • Benzenoid
  • Monosaccharide
  • Tertiary alcohol
  • Vinylogous acid
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Ketone
  • Polyol
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Acetal
  • Alcohol
  • Primary alcohol
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Primary aliphatic amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Biological Properties
StatusDetected and Not Quantified
OriginNot Available
Cellular LocationsNot Available
Biofluid LocationsNot Available
Tissue LocationsNot Available
PathwaysNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Physical Properties
StateNot Available
AppearanceNot Available
Experimental Properties
PropertyValue
Melting PointNot Available
Boiling PointNot Available
SolubilityNot Available
Predicted Properties
PropertyValueSource
Water Solubility1.49 g/LALOGPS
logP0.35ALOGPS
logP0.23ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)9.74ChemAxon
pKa (Strongest Basic)9.14ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area209.23 ŲChemAxon
Rotatable Bond Count5ChemAxon
Refractivity135.36 m³·mol⁻¹ChemAxon
Polarizability55.18 ųChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash KeyView
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positivesplash10-05cu-9202330000-293431fa9a3beabb905aSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (2 TMS) - 70eV, Positivesplash10-05cr-9100027000-9c9cf29a2155532f09afSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS ("Doxorubicinol,1TMS,#1" TMS) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_1_1) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_1_2) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_1_3) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_1_4) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_1_5) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_1_6) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_1_7) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_2) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_3) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_4) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_5) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_6) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_7) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_8) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_9) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_10) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_11) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_12) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_13) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_14) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_15) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (TMS_2_16) - 70eV, PositiveNot AvailableSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-002b-0005590000-43113f22c78fca74fdebSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0002-0329320000-a332c43d10c0b4ddb96dSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0a4s-5109200000-ef48a2d5eeff5f4ea3e0Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0006-1002290000-c9423b92582d5ee5ae84Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-016u-5207930000-fe3a4fe0aab942bc7aaaSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-014i-5208900000-fcd2c6340e9ee5713649Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-000t-0309030000-5206d6f53daa8bf225e5Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-001j-1908140000-b0829ffd6899d23dcb4bSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-01q9-3942100000-2fd7b4b2545a5c6f29fbSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0007-0009380000-9e9af25452210d38af65Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-015j-0009100000-a36a411ed5f6ef85d51dSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-00ke-0009220000-64f663944cf9e55c689cSpectrum
Toxicity Profile
Route of ExposureNot Available
Mechanism of ToxicityNot Available
MetabolismNot Available
Toxicity ValuesNot Available
Lethal DoseNot Available
Carcinogenicity (IARC Classification)Not Available
Uses/SourcesNot Available
Minimum Risk LevelNot Available
Health EffectsNot Available
SymptomsNot Available
TreatmentNot Available
Concentrations
Not Available
DrugBank IDNot Available
HMDB IDHMDB0041884
FooDB IDNot Available
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG IDNot Available
BioCyc IDNot Available
METLIN IDNot Available
PDB IDNot Available
Wikipedia LinkNot Available
Chemspider ID75768
ChEBI ID133817
PubChem Compound ID83970
Kegg Compound IDNot Available
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis ReferenceNot Available
MSDSNot Available
General References
1. https://www.ncbi.nlm.nih.gov/pubmed/?term=10408701
2. https://www.ncbi.nlm.nih.gov/pubmed/?term=11448472
3. https://www.ncbi.nlm.nih.gov/pubmed/?term=12647011
4. https://www.ncbi.nlm.nih.gov/pubmed/?term=16168722
5. https://www.ncbi.nlm.nih.gov/pubmed/?term=1628370
6. https://www.ncbi.nlm.nih.gov/pubmed/?term=16614166
7. https://www.ncbi.nlm.nih.gov/pubmed/?term=16915573
8. https://www.ncbi.nlm.nih.gov/pubmed/?term=16958789
9. https://www.ncbi.nlm.nih.gov/pubmed/?term=17197005
10. https://www.ncbi.nlm.nih.gov/pubmed/?term=17379584
11. https://www.ncbi.nlm.nih.gov/pubmed/?term=18371724
12. https://www.ncbi.nlm.nih.gov/pubmed/?term=18967867
13. https://www.ncbi.nlm.nih.gov/pubmed/?term=19174209
14. https://www.ncbi.nlm.nih.gov/pubmed/?term=23192654
15. https://www.ncbi.nlm.nih.gov/pubmed/?term=23337906
16. https://www.ncbi.nlm.nih.gov/pubmed/?term=24631816
17. https://www.ncbi.nlm.nih.gov/pubmed/?term=25446851
18. https://www.ncbi.nlm.nih.gov/pubmed/?term=27447545
19. https://www.ncbi.nlm.nih.gov/pubmed/?term=2897122
20. https://www.ncbi.nlm.nih.gov/pubmed/?term=8298821
21. https://www.ncbi.nlm.nih.gov/pubmed/?term=8595168
22. https://www.ncbi.nlm.nih.gov/pubmed/?term=9261889
23. https://www.ncbi.nlm.nih.gov/pubmed/?term=9696578
24. https://www.ncbi.nlm.nih.gov/pubmed/?term=9888978
25. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH: Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer. 1999 Jan;79(1):108-13.
26. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L: A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother Pharmacol. 2003 Feb;51(2):107-18. Epub 2003 Jan 10.
27. Bressolle F, Jacquet JM, Galtier M, Jourdan J, Donadio D, Rossi JF: Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol. 1992;30(3):215-8.
28. Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore AM, Gianni L, Minotti G: Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther. 2006 Jul;318(1):424-33. Epub 2006 Apr 13.
29. Eder AR, Chen JS, Arriaga EA: Separation of doxorubicin and doxorubicinol by cyclodextrin-modified micellar electrokinetic capillary chromatography. Electrophoresis. 2006 Aug;27(16):3263-70.
30. Gilbert CM, Filippich LJ, McGeary RP, Charles BG: Pharmacokinetics of doxorubicinol in dogs. J Vet Pharmacol Ther. 2006 Oct;29(5):433-5.
31. DiFrancesco R, Griggs JJ, Donnelly J, DiCenzo R: Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):545-53. Epub 2007 Feb 24.
32. Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G: The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther. 2013 Feb;344(2):467-78. doi: 10.1124/jpet.112.200568. Epub 2012 Nov 28.
33. Sottani C, Poggi G, Melchiorre F, Montagna B, Minoia C: Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC-MS/MS in human plasma of HCC patients treated with TACE. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Feb 1;915-916:71-8. doi: 10.1016/j.jchromb.2012.12.012. Epub 2012 Dec 22.
34. Perez-Blanco JS, Fernandez de Gatta Mdel M, Hernandez-Rivas JM, Garcia Sanchez MJ, Sayalero Marinero ML, Gonzalez Lopez F: Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 1;955-956:93-7. doi: 10.1016/j.jchromb.2014.02.034. Epub 2014 Feb 28.
35. Schaupp CM, White CC, Merrill GF, Kavanagh TJ: Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3. Chem Biol Interact. 2015 Jun 5;234:154-61. doi: 10.1016/j.cbi.2014.11.010. Epub 2014 Nov 21.
36. Perez-Blanco JS, Santos-Buelga D, Fernandez de Gatta MD, Hernandez-Rivas JM, Martin A, Garcia MJ: Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. Br J Clin Pharmacol. 2016 Dec;82(6):1517-1527. doi: 10.1111/bcp.13070. Epub 2016 Sep 6.
37. Lee HJ, Lee MG: Pharmacokinetics of adriamycin and adriamycinol after intravenous administration of adriamycin to rats with water-deprivation for 48 hours. Res Commun Mol Pathol Pharmacol. 1997 Jun;96(3):299-306.
38. Fraier D, Frigerio E, Pianezzola E, Strolin Benedetti M, Cassidy J, Vasey P: A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection. J Pharm Biomed Anal. 1995 Apr;13(4-5):625-33.
39. de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G, Sparreboom A: Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem. 1999 Jan 15;266(2):216-21.